After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback